Prognostic Role of MicroRNA-126 for Survival in Malignant Tumors: A Systematic Review and Meta-Analysis

Table 1

Main characteristics of enrolled studies in the systematic review.

Author	Year	Country	Cancer	Number	Specimen	Assay	Cut-off value	Source of HR	Endpoint	Median follow-up (months)
Shibayama et al. [36]	2015	Japan	AML	108	Bone marrow	qRT-PCR	Median	R	OS	NR
Ishihara et al. [37]	2012	Japan	ATL	35	Plasma	qRT-PCR	Median	SC	OS	NR
de Leeuw et al. [38]	2014	Netherlands	AML	92	Blood	qRT-PCR	Median	R	OS, EFS, RFS	NR
Sanfiorenzo et al. [39]	2013	France	NSCLC	52	Plasma	qRT-PCR	Median	R	DFS	46
Donnem et al. [40]	2011	Norway	NSCLC	332	Tissue	ISH	Expression score ≥ 2	R	DSS^a	86
Kim et al. [41]	2014	South Korea	NSCLC	72	Tissue	qRT-PCR	Median	R	OS	31
Jusufović et al. [42]	2012	Serbia	NSCLC	50	Tissue	qRT-PCR	Median	R	OS, PFS	5.13
Yang et al. [43]	2012	China	NSCLC	442	Tissue	qRT-PCR	Median	R	OS	24.39–29.28
Li et al. [44]	2014	China	NSCLC	49	Tissue	qRT-PCR	Median	SC	OS, DFS	39
Han et al. [45]	2012	China	HCC	105	Tissue	qRT-PCR	Fold change = 2	R	OS	42.89
Chen et al. [46]	2013	China	HCC	68	Tissue	qRT-PCR	0.70 (ROC curve)	SC	OS	49
Yang et al. [47]	2014	China	Cervical cancer	133	Tissue	qRT-PCR	Median	R	OS	60 (max)
Sun et al. [48]	2014	China	LSCC	38	Plasma	qRT-PCR	Median	SC	OS	NR
Hansen et al. [49]	2012	Denmark	CRC	89	Tissue	ISH	Median	SC	PFS	16.8–26.2
Hansen et al. [50]	2014	Denmark	CRC	63	Plasma	qRT-PCR	Median	R	PFS	8.8–9.2
Li et al. [51]	2013	China	Colon cancer	53	Tissue	ISH	0/1–3+	SC	OS	45.66–55.04
Liu et al. [52]	2014	China	CRC	92	Tissue	qRT-PCR	Median	SC	OS	65
Díaz et al. [53]	2008	Spain	Colon cancer	110	Tissue	qRT-PCR	Median	R	OS, DFS	68
Hansen et al. [54]	2011	Denmark	CRC	81	Tissue	ISH	Median	R	OS, PFS	NR
Hansen et al. [55]	2013	Denmark/Sweden	CRC	89	Tissue	qRT-PCR	Median	R	PFS	NR
Hansen et al. [56]	2015	Denmark	CRC	560	Tissue	qRT-PCR	Median	R	OS, DSS	7 years (max)
Sasahira et al. [57]	2012	Japan	Oral cancer	94	Tissue	qRT-PCR	Means	R	DFS	3.4 years
Sun et al. [58]	2013	China	Prostate cancer	128	Tissue	qRT-PCR	Median	SC	RFS	3–10 years
Hoppe et al. [59]	2013	Germany	Breast cancer	80	Tissue	qRT-PCR	6.20 (ROC curve)	R	RFS	8.84 years
Vergho et al. [60]	2014	Germany	cRCC	37	Tissue	qRT-PCR	3.57 (ROC curve)	R	DSS	41.4
Khella et al. [61]	2015	Canada	cRCC	257,481^b	Tissue	qRT-PCR	20th percentile	R	OS, DFS, OS^b	48.6
Liu et al. [62]	2015	China	ESCC	185	Tissue	ISH	Fold change > 3	R	DSS	32
Hu et al. [63]	2011	USA	ESCC	158	Tissue	ISH	1–3+/0–0.5	R	OS, DFS	16.25
Wang et al. [64]	2013	China	ESCC	116	Tissue	qRT-PCR	CT < −1	SC	DFS	21–32
Feng et al. [65]	2012	USA	GBM	248	Tissue	qRT-PCR	Median	R	PFS/RFS^b, OS^b	NR

CRC: colorectal cancer; HCC: hepatocellular carcinoma; NSCLC: non-small cell lung cancer; cRCC: clear renal cell carcinoma; ESCC: esophageal squamous cell carcinoma; AML: acute myeloid leukemia; ATL: adult T-cell leukemia; LSCC: laryngeal squamous cell carcinoma; GBM: glioblastoma multiforme; qRT-PCR: quantitative real-time PCR; ISH: in situ hybridization; OS: overall survival; DFS: disease-free survival; RFS: recurrence-free survival; PFS: progression-free survival; DSS: disease-specific survival; HR: hazard ratio; SC: survival curve; NR: not reported; R: reported.
^aDSS included any of the following: DSS, CSS (cancer-specific survival). ^bData extracted from TCGA (The Cancer Genome Atlas) in the paper.